{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:35:12Z","timestamp":1793910912845,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jbo.2022.100430","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T11:03:52Z","timestamp":1650107032000},"page":"100430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Makoto","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukino","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayuna","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Tanzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issay","family":"Kitabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbo.2022.100430_b0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1302\/0301-620X.82B1.0820055","article-title":"Experience in the treatment of dedifferentiated chondrosarcoma","volume":"82","author":"Mitchell","year":"2000","journal-title":"J. Bone Joint Surg. Br."},{"issue":"11","key":"10.1016\/j.jbo.2022.100430_b0010","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5897","key":"10.1016\/j.jbo.2022.100430_b0015","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jbo.2022.100430_b0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.jbo.2022.100430_b0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"issue":"42","key":"10.1016\/j.jbo.2022.100430_b0030","doi-asserted-by":"crossref","first-page":"6835","DOI":"10.1038\/s41388-019-0929-9","article-title":"Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma","volume":"38","author":"Nakagawa","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jbo.2022.100430_b0035","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-019-12525-7","article-title":"Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression","volume":"10","author":"Nicolle","year":"2019","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jbo.2022.100430_b0040","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.18632\/oncotarget.3330","article-title":"D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth","volume":"6","author":"Ma","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jbo.2022.100430_b0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1535-7163.MCT-18-1349","article-title":"A potent blood-brain barrier-permeable mutant IDH1 inhibitor suppresses the growth of glioblastoma with IDH1 mutation in a patient-derived orthotopic xenograft model","volume":"19","author":"Machida","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.jbo.2022.100430_b0050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon-2016-0226","article-title":"Novel therapeutic approaches in chondrosarcoma","volume":"13","author":"Polychronidou","year":"2017","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2022.100430_b0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10637-019-00771-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors","volume":"38","author":"Fan","year":"2020","journal-title":"Invest. New Drugs"},{"issue":"6","key":"10.1016\/j.jbo.2022.100430_b0060","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.jbo.2022.100430_b0065","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2022.100430_b0070","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.14018","article-title":"Characterisation of isocitrate dehydrogenase 1\/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma","volume":"76","author":"Mohammad","year":"2020","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.jbo.2022.100430_b0075","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1634\/theoncologist.2014-0266","article-title":"Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma","volume":"20","author":"Lombardi","year":"2015","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.jbo.2022.100430_b0080","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-13-2649","article-title":"Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma","volume":"20","author":"Borger","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2022.100430_b0085","article-title":"Prognostic impact of IDH mutations in chondrosarcoma","author":"Nakagawa","year":"2021","journal-title":"J. Orthop. Sci."},{"issue":"3","key":"10.1016\/j.jbo.2022.100430_b0090","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.bbrc.2012.06.002","article-title":"IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells","volume":"423","author":"Matsunaga","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.jbo.2022.100430_b0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000055338","article-title":"The clinical significance of tenascin-C splice variant expression in chondrosarcoma","volume":"61","author":"Ghert","year":"2001","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.jbo.2022.100430_b0100","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00428-007-0426-3","article-title":"Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation","volume":"451","author":"Kudo","year":"2007","journal-title":"Virchows Arch."},{"issue":"2","key":"10.1016\/j.jbo.2022.100430_b0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2990.2000.026002172.x","article-title":"Cryopreservation of viable human glioblastoma xenografts","volume":"26","author":"Goike","year":"2000","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"6","key":"10.1016\/j.jbo.2022.100430_b0110","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/mrm.1910290613","article-title":"Automatic, localized in Vivo adjustment of all first-and second-order shim coils","volume":"29","author":"Gruetter","year":"1993","journal-title":"Magn. Reson. Med."},{"issue":"8","key":"10.1016\/j.jbo.2022.100430_b0115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/mrc.1053","article-title":"1H and13C NMR study of 2-hydroxyglutaric acid and its lactone","volume":"40","author":"Bal","year":"2002","journal-title":"Magn. Reson. Chem."},{"issue":"3","key":"10.1016\/j.jbo.2022.100430_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2463\/mrms.2013-0089","article-title":"Recovery correction technique for NMR spectroscopy of perchloric acid extracts using DL-valine-2,3\u2013d2: validation and application to 5-fluorouracil-induced brain damage","volume":"13","author":"Nakagami","year":"2014","journal-title":"Magn. Reson. Med. Sci."},{"issue":"2","key":"10.1016\/j.jbo.2022.100430_b0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/1078-0432.CCR-18-4212","article-title":"Genomic profiling identifies association of IDH1\/IDH2 mutation with longer relapse-free and metastasis-free survival in high-grade chondrosarcoma","volume":"26","author":"Zhu","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jbo.2022.100430_b0130","doi-asserted-by":"crossref","first-page":"998","DOI":"10.7150\/jca.22915","article-title":"IDH1\/2 mutations predict shorter survival in chondrosarcoma","volume":"9","author":"Lugowska","year":"2018","journal-title":"J Cancer"},{"issue":"13","key":"10.1016\/j.jbo.2022.100430_b0135","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1002\/cam4.4019","article-title":"Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis","volume":"10","author":"Vuong","year":"2021","journal-title":"Cancer Med"},{"issue":"24","key":"10.1016\/j.jbo.2022.100430_b0140","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2013-03-493197","article-title":"Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia","volume":"121","author":"DiNardo","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbo.2022.100430_b0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1750-3639.2009.00352.x","article-title":"Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors","volume":"20","author":"Capper","year":"2010","journal-title":"Brain Pathol."},{"issue":"4","key":"10.1016\/j.jbo.2022.100430_b0150","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G","article-title":"In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time","volume":"41","author":"Tk\u00e1c","year":"1999","journal-title":"Magn. Reson. Med."},{"issue":"116","key":"10.1016\/j.jbo.2022.100430_b0155","doi-asserted-by":"crossref","first-page":"116ra4","DOI":"10.1126\/scitranslmed.3002693","article-title":"Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy","volume":"4","author":"Andronesi","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.jbo.2022.100430_b0160","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jbo.2022.100430_b0165","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/mrm.20829","article-title":"In vivo localized 1H MR spectroscopy of rat testes: stimulated echo acquisition mode (STEAM) combined with short TI inversion recovery (STIR) improves the detection of metabolite signals","volume":"55","author":"Yamaguchi","year":"2006","journal-title":"Magn. Reson. Med."},{"issue":"6","key":"10.1016\/j.jbo.2022.100430_b0170","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mrm.1910300604","article-title":"Estimation of metabolite concentrations from localized in vivo proton NMR spectra","volume":"30","author":"Provencher","year":"1993","journal-title":"Magn. Reson. Med."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:18:35Z","timestamp":1761941915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137422000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":34,"alternative-id":["S2212137422000203"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100430","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100430"}}